Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:417-419, 2006
DOI: 10.2337/diacare.29.02.06.dc05-2223
© 2006 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, K.
Right arrow Articles by Yagi, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, K.
Right arrow Articles by Yagi, N.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clinical Care/Education/Nutrition
Brief Report

Diet Therapy With Diacylglycerol Oil Delays the Progression of Renal Failure in Type 2 Diabetic Patients With Nephropathy

Kunio Yamamoto, MS1, Kazuichi Tomonobu, MS2, Hideki Asakawa, MD, PHD3, Katsuto Tokunaga, MD, PHD4, Tadashi Hase, MS2, Ichiro Tokimitsu, PHD2 and Noriko Yagi, PHD1

1 Department of Nutrition, Graduate School of Nutrition, Koshien University, Takarazuka, Hyogo, Japan
2 Health Care Products Research Laboratories No. 1, Kao Corporation, Bunka, Sumida-ku, Tokyo, Japan
3 Department of Internal Medicine, Suita Municipal Hospital, Suita, Osaka, Japan
4 Department of Internal Medicine, Itami City Hospital, Itami, Hyogo, Japan

Address correspondence and reprint requests to Kazuichi Tomonobu, Health Care Products Research Laboratories No.1, Kao Corporation, 2-1-3 Bunka, Sumida-ku, Tokyo 131-8501, Japan. E-mail: tomonobu.kazuichi@kao.co.jp

Abbreviations: DAG, diacylglycerol

The first 20% of the full text of this article appears below.


   INTRODUCTION
 
Diet therapy for diabetic nephropathy is important in preventing the progression of renal failure by controlling hyperglycemia, hypertension, hyperlipidemia, and obesity (1,2). Edible oil containing mainly diacylglycerol (DAG) oil, compared with conventional triacylglycerol oil, has been reported to possess unique nutritional properties with respect to serum lipids and body fat metabolism (3–6). We previously reported that a 3-month intake of DAG oil significantly reduced fasting serum triglycerides in subjects of type 2 diabetes with hypertriglyceridemia (7).

In the present study, we conducted a further clinical study for 6 months with an additional 3-year follow-up period to investigate the long-term effects of DAG oil in dietary therapy in subjects with type 2 diabetes with nephropathy.


   RESEARCH DESIGN AND METHODS
 
The subjects were 15 outpatients (aged 47–77 years) at the Itami City Hospital who were diagnosed with type 2 diabetes in stage IIIb (macroalbuminuric stage with renal dysfunction; n = 2) and stage IV (renal failure stage; n = 13) according to the classification of diabetic nephropathy (Ministry of Health and Welfare, Japan) (8) who were receiving nutritional counseling for 13 months on average. The duration of diabetes was 18.2 ± 7.8 (range 5–28) years. Subjects . . . [Full Text of this Article]


   RESULTS
 

   CONCLUSIONS
 

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2006 by the American Diabetes Association.